|
| 舒更葡糖钠在病态肥胖患者麻醉管理中的研究进展 |
| Research progress of sugammadex in anesthesia management for patients with morbid obesity |
| |
| DOI：10.12089/jca.2026.05.012 |
| 中文关键词: 舒更葡糖钠 病态肥胖 术后肌松残余 麻醉苏醒延迟 术后肺部并发症 |
| 英文关键词: Sugammadex Morbid obesity Postoperative residual curarization Delayed emergence from anesthesia Postoperative pulmonary complications |
| 基金项目: |
|
| 摘要点击次数: 765 |
| 全文下载次数: 222 |
| 中文摘要: |
| 病态肥胖患者围术期发生严重气道并发症的风险是普通患者的4倍，此类患者的围术期呼吸系统管理对麻醉科医师尤其具有挑战性。舒更葡糖钠作为一种非去极化肌松药的特异性拮抗药，在临床中常被用于快速逆转神经肌肉阻滞，相较于传统拮抗药新斯的明，其逆转肌松速度更快，能显著降低病态肥胖患者术后肌松残余和术后肺部并发症的发生率，并促进胃肠功能恢复，加速患者康复。本文就目前舒更葡糖钠在病态肥胖患者中的应用进展、合适剂量、联合使用策略作一概述，为优化病态肥胖患者的麻醉管理提供参考。 |
| 英文摘要: |
| The risk of severe airway complications during the perioperative period in patients with morbid obesity is four times higher than that in the general population. Therefore, perioperative respiratory management in morbidly obese patients is particularly challenging for anesthesiologists. Sugammadex, as a specific antagonist of non-depolarizing muscle relaxants, is commonly used in clinical practice to rapidly reverse neuromuscular blockade.Compared with the traditional antagonist neostigmine, sugammadex reverses neuromuscular blockade more rapidly, significantly reduces the incidence of postoperative residual curarization and postoperative pulmonary complications in morbidly obese patients, and promotes gastrointestinal function recovery, thereby accelerating patients' rehabilitation. This article provides an overview of the current application progress of sugammadex in patients with morbid obesity, including appropriate dosing and combination strategies, offering reference for optimizing anesthesia management in these patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
